Helvie Mark A, Bailey Janet E, Roubidoux Marilyn A, Pass Helen A, Chang Alfred E, Pierce Lori J, Wilkins Edwin G
Department of Radiology, University of Michigan Health System, 1500 E Medical Center Dr, Taubman Center 2910N, Ann Arbor, MI 48109-0326, USA.
Radiology. 2002 Jul;224(1):211-6. doi: 10.1148/radiol.2241010061.
To evaluate findings from routine mammographic screenings in patients with transverse rectus abdominis musculocutaneous (TRAM) flap reconstructions.
During a 25-month study period, 214 consecutive screening mammograms in 113 asymptomatic women (mean age, 51 years) with TRAM flap reconstructions were obtained. Mastectomies were performed for cancer in 106 (94%) of the 113 women and for prophylaxis in seven (6%). Prospectively, a Breast Imaging Reporting and Data System (BI-RADS) assessment category 1-5 was assigned to each mammogram. Surgical, medical, pathologic, and radiographic records were retrospectively reviewed. CIs were determined by the normal approximation to the binomial distribution.
Seven (3%) of 214 examinations were BI-RADS category 4 or 5. Six (86%) of seven patients underwent biopsy. Two (33%) of these six biopsies demonstrated invasive ductal carcinoma. Cancer detection rate for mammography was 1.9% (two of 106) (95% CI: 0.33%, 7.32%) for women with reconstruction for breast cancer during the 2-year period. One (6%) of 16 BI-RADS category 3 examinations later proved to be invasive ductal carcinoma at follow-up. No interval cancer was discovered in 171 cases of BI-RADS category 1 or 2 examinations with 1-year follow-up. No cancers occurred in women who underwent prophylactic mastectomy. A biopsy positive predictive value of 33% (95% CI: 6%, 76%) was observed.
Screening mammography of TRAM flap-reconstructed breasts enables detection of nonpalpable cancer before clinical examination.
评估腹直肌肌皮瓣(TRAM)重建患者常规乳腺钼靶筛查的结果。
在为期25个月的研究期间,对113例无症状且接受了TRAM瓣重建的女性(平均年龄51岁)进行了连续214次乳腺钼靶筛查。113例女性中,106例(94%)因癌症行乳房切除术,7例(6%)因预防目的行乳房切除术。前瞻性地,为每例乳腺钼靶检查指定一个乳腺影像报告和数据系统(BI-RADS)评估类别1-5。对手术、医学、病理和影像学记录进行回顾性审查。置信区间通过二项分布的正态近似确定。
214次检查中有7次(3%)为BI-RADS类别4或5。7例患者中有6例(86%)接受了活检。这6例活检中有2例(33%)显示为浸润性导管癌。在2年期间,乳腺癌重建女性的乳腺钼靶癌症检出率为1.9%(106例中有2例)(95%置信区间:0.33%,7.32%)。16例BI-RADS类别3检查中有1例(6%)在随访时被证实为浸润性导管癌。在171例BI-RADS类别1或2检查且随访1年的病例中未发现间期癌。接受预防性乳房切除术的女性未发生癌症。观察到活检阳性预测值为33%(95%置信区间:6%,76%)。
对TRAM瓣重建乳房进行乳腺钼靶筛查能够在临床检查之前检测出不可触及的癌症。